Trevena Is Toast
(WorldNews Health)

Shares of biotech Trevena (TRVN) have fallen below $1 as the market digested the negative implications of a highly contentious review from the FDA´s Anesthetic and Analgesic Advisory Committee review and eight to seven vote against approving the company´s lead drug candidate, Oliceridine. Given the hostile tone of the FDA minutes, the negative view on safety, and the negative vote on approval, I believe shares of Trevena are essentially worthless, as I do not believe Oliceridine will be approved. Negative FDA Tone Demonstrates Poor Agency Communication and Approval Process Knowledge One of the most damning parts of the entire Advisory Committee process for Trevena was the negative tone from...